Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OCUL
Previous Symbol
CUSIPN/A
Phone781-357-4000
Debt
Debt-to-Equity Ratio0.18
Current Ratio4.35
Quick Ratio4.34
Price-To-Earnings
Trailing P/E Ratio-2.65
Forward P/E Ratio-3.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.92 million
Price / Sales124.80
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.72 per share
Price / Book8.10
Profitability
EPS (Most Recent Fiscal Year)($2.20)
Net Income$-63,380,000.00
Net Margins-2,822.15%
Return on Equity-133.73%
Return on Assets-81.64%
Miscellaneous
Employees119
Outstanding Shares41,100,000
Market Cap$239.18 million
OptionableOptionable
Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix Inc (NASDAQ:OCUL) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.02. The biopharmaceutical company earned $0.50 million during the quarter, compared to the consensus estimate of $0.45 million. Ocular Therapeutix had a negative return on equity of 133.73% and a negative net margin of 2,822.15%. View Ocular Therapeutix's Earnings History.
When is Ocular Therapeutix's next earnings date?
What price target have analysts set for OCUL?
7 analysts have issued 12-month target prices for Ocular Therapeutix's stock. Their predictions range from $9.00 to $24.00. On average, they expect Ocular Therapeutix's stock price to reach $13.60 in the next twelve months. This suggests a possible upside of 133.3% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix.
What is the consensus analysts' recommendation for Ocular Therapeutix?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix.
What are Wall Street analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- 1. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $573M, which includes a discounted cash flow-based asset value of $580M for DEXTENZA, OTX-TP and ReSure, and excludes projected debt position of $7M at the end of 2019, using a 15% discount rate and 2% terminal growth rate, and assuming 47.7M shares outstanding at the end of 2019. Probabilities of success ascribed to post-surgical ocular pain and inflammation, allergic conjunctivitis and glaucoma are 100%, 40% and 40%, respectively." (12/4/2018)
- 2. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (11/14/2018)
- 3. Cantor Fitzgerald analysts commented, "We rate Ocular Therapeutix (OCUL) 12-month price target of $22 per share. Ocular focuses on a platform of sustained drug-delivered therapies for the treatment of ocular diseases and conditions. Ocular’s lead development product, DEXTENZA, is an intracanalicular dexamethasone insert therapy for the treatment of post-surgical ocular pain. We believe Ocular could receive FDA approval in 2018. Valuation Summary We arrive at our 12-month price target of $22/share by assessing the after-tax, risk- adjusted NPV of future cash flows from DEXTENZA." (7/19/2018)
Has Ocular Therapeutix been receiving favorable news coverage?
Media stories about OCUL stock have trended somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ocular Therapeutix earned a news sentiment score of 1.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX), Dicerna Pharmaceuticals (DRNA), ImmunoGen (IMGN), Y-mAbs Therapeutics (YMAB), Lexicon Pharmaceuticals (LXRX), AC Immune (ACIU), Principia Biopharma (PRNB) and Radius Health (RDUS).
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Dr. Amarpreet Sawhney, Founder & Exec. Chairman (Age 51)
- Mr. Antony Mattessich, Pres, CEO & Director (Age 51)
- Mr. Donald Notman Jr., Chief Financial Officer
- Dr. Michael H. Goldstein, Chief Medical Officer (Age 51)
- Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 56)
Who are Ocular Therapeutix's major shareholders?
Ocular Therapeutix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (6.05%), FMR LLC (5.96%), BlackRock Inc. (5.94%), Vanguard Group Inc. (3.47%), Opaleye Management Inc. (1.95%) and Deltec Asset Management LLC (1.61%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Institutional Ownership Trends for Ocular Therapeutix.
Which institutional investors are selling Ocular Therapeutix stock?
Which institutional investors are buying Ocular Therapeutix stock?
OCUL stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, BlackRock Inc., Vanguard Group Inc., Deltec Asset Management LLC, Hikari Power Ltd, Dimensional Fund Advisors LP, Trexquant Investment LP and Jennison Associates LLC. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Insider Buying and Selling for Ocular Therapeutix.
How do I buy shares of Ocular Therapeutix?
Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of OCUL stock can currently be purchased for approximately $5.83.
How big of a company is Ocular Therapeutix?
Ocular Therapeutix has a market capitalization of $239.18 million and generates $1.92 million in revenue each year. The biopharmaceutical company earns $-63,380,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Ocular Therapeutix employs 119 workers across the globe.
What is Ocular Therapeutix's official website?
How can I contact Ocular Therapeutix?
Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]
MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
